RKRoosa E. Kallionpää

Roosa E. Kallionpää

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roosa E. Kallionpää has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Katja Valli

    Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Turku, Finland

    7 shared publications
  • Antti Revonsuo

    Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Turun yliopisto, Finland; Department of Cognitive Neuroscience and Philosophy, School of Bioscience, University of Skövde, Skövde, Sweden

    4 shared publications
  • A. Revonsuo

    Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Turku, Finland; Department of Cognitive Neuroscience and Philosophy, School of Bioscience, University of Skövde, Skövde, Sweden

    3 shared publications
  • A. Scheinin

    Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland; Department of Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland

    3 shared publications
  • Annalotta Scheinin

    Department of Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland; Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland

    3 shared publications
  • Carlos Rogerio Figueiredo

    Medical Immune Oncology Research Group (MIORG), Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland

    3 shared publications

Latest Publications

  • Open Access

    Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune‐Associated Biomarkers of Anti‐ PD1 Response in Metastatic Melanoma

    by S. A. Koskela, R. E. Kallionpää, I. Mäkelä, E.‐M. Birkman, M. Sundvall, C. R. Figueiredo

    Resistance to anti‐PD1 therapy remains a major challenge in metastatic melanoma, despite long‐term benefit in some patients. Since a functional dendritic cell (DC)‐CD8 + T cell axis is essential for anti‐PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC‐CD8 + T cell axis in melanoma, evaluating their associations with anti‐PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre‐treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker‐associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non‐responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment‐ and site‐specific. Among them, FAM57A , GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45 + immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K‐AKT‐mTORC1/MAPK signalling, especially upon co‐expression. Together, these results identify FAM57A , GSTA4 and KCTD1 as emerging immune‐associated biomarkers linked to established resistance‐associated immune states and poor prognosis in metastatic melanoma.

  • Open Access

    Novel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology

    by Carlos Figueiredo, Saara Koskela, Otto Pulkkinen, Arfa Mehmood, Roosa Kallionpää, Eva-Maria Birkman, Jani Huuhtanen, Satu Mustjoki, Sarah Coupland, Tero Aittokallio, et al.

    Despite the success of anti-PD1 immunotherapy in melanoma, identifying biomarkers for response prediction and rational treatment combinations remains a major challenge. Effective dendritic cell (DC):CD8+ T cell crosstalk in the tumor microenvironment enhances anti-PD1 responses; however, no predictive signatures reflect this interaction. To address this, we developed a systems immunology approach based on DC:CD8+ T cell crosstalk reference biomarkers CD74 and CD8A, leading to the discovery of a 15-gene immune signature called PRIME, incorporated into a logistic regression framework for anti-PD1 response prediction in melanoma. PRIME outperforms previous signatures, especially in tumors with high CD8+ T cells, reflecting a functional immune response. Integrating clinical, molecular, spatial, and single-cell profiling identified SLAMF7 and TYMP as new functional biomarker candidates in DCs. Mechanistic studies revealed that these biomarkers regulate antigen processing and presentation in DCs. Our study demonstrates a new strategy for predicting anti-PD1 responses in melanoma, revealing biomarkers with functional roles that may inform future therapeutic development.


  • The relationship of bispectral index values to conscious state: an analysis of two volunteer cohort studies

    by Jordan J. Wehrman, Peter J. Schuller, Cameron P. Casey, Annalotta Scheinin, Roosa E. Kallionpää, Katja Valli, Antti Revonsuo, Oskari Kantonen, Sean Tanabe, William Filbey, et al.


  • Open Access

    TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity

    by Miriam Langguth, Eleftheria Maranou, Saara A. Koskela, Oskar Elenius, Roosa E. Kallionpää, Eva-Maria Birkman, Otto I. Pulkkinen, Maria Sundvall, Marko Salmi, Carlos R. Figueiredo

    Immune checkpoint therapies (ICT) for advanced solid tumors mark a new milestone in cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to inadequate priming and generation of antitumor T cells by dendritic cells (DCs). Identifying biomarkers to enhance DC functions in such tumors is thus crucial. Tissue Inhibitor of Metalloproteinases-1 (TIMP-1), recognized for its influence on immune cells, has an underexplored relationship with DCs. Our research reveals a correlation between high TIMP1 levels in metastatic melanoma and increased CD8 + T cell infiltration and survival. Network studies indicate a functional connection with HLA genes. Spatial transcriptomic analysis of a national melanoma cohort revealed that TIMP1 expression in immune compartments associates with an HLA-A/MHC-I peptide loading signature in lymph nodes. Primary human and bone-marrow-derived DCs secrete TIMP-1, which notably increases MHC-I expression in classical type 1 dendritic cells (cDC1), especially under melanoma antigen exposure. TIMP-1 affects the immunoproteasome/TAP complex, as seen by upregulated PSMB8 and TAP-1 levels of myeloid DCs. This study uncovers the role of TIMP-1 in DC-mediated immunogenicity with insights into CD8 + T cell activation, providing a foundation for mechanistic exploration and highlighting its potential as a new target for combinatorial immunotherapy to enhance ICT effectiveness.


  • Open Access

    Cancer‐associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma

    by Jaakko S. Knuutila, Pilvi Riihilä, Liisa Nissinen, Lauri Heiskanen, Roosa E. Kallionpää, Teijo Pellinen, Veli‐Matti Kähäri

    Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer and the metastatic disease is associated with poor prognosis. Cancer‐associated fibroblasts (CAFs) promote progression of cancer, but their role in cSCC is largely unknown. We examined the potential of CAF markers in the assessment of metastasis risk and prognosis of primary cSCC. We utilized multiplexed fluorescence immunohistochemistry for profiling CAF landscape in metastatic and non‐metastatic primary human cSCCs, in metastases, and in premalignant epidermal lesions. Quantitative high‐resolution image analysis was performed with two separate panels of antibodies for CAF markers and results were correlated with clinical and histopathological parameters including disease‐specific mortality. Increased stromal expression of fibroblast activation protein (FAP), α‐smooth muscle actin, and secreted protein acidic and rich in cysteine (SPARC) were associated with progression to invasive cSCC. Elevation of FAP and platelet‐derived growth factor receptor‐β (PDGFRβ) expression was associated with metastasis risk of primary cSCCs. High expression of PDGFRβ and periostin correlated with poor prognosis. Multimarker combination defined CAF subset, PDGFRα−/PDGFRβ+/FAP+, was associated with invasion and metastasis, and independently predicted poor disease‐specific survival. These results identify high PDGFRβ expression alone and multimarker combination PDGFRα−/PDGFRβ+/FAP+ by CAFs as potential biomarkers for risk of metastasis and poor prognosis.


  • Open Access

    Subjective experiences during dexmedetomidine- or propofol-induced unresponsiveness and non-rapid eye movement sleep in healthy male subjects

    by Katja Valli, Linda Radek, Roosa E. Kallionpää, Annalotta Scheinin, Jaakko Långsjö, Kaike Kaisti, Oskari Kantonen, Jarno Korhonen, Tero Vahlberg, Antti Revonsuo, et al.


  • Publisher Correction: Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis

    by Paulina Moreno-Layseca, Niklas Z. Jäntti, Rashmi Godbole, Christian Sommer, Guillaume Jacquemet, Hussein Al-Akhrass, James R. W. Conway, Pauliina Kronqvist, Roosa E. Kallionpää, Leticia Oliveira-Ferrer, et al.


  • Open Access

    Increased incidence of melanoma in children and adolescents in Finland in 1990–2014: nationwide re-evaluation of histopathological characteristics

    by Emma K. Rousi, Roope A. Kallionpää, Roosa E. Kallionpää, Susanna M. Juteau, Lauri A. I. Talve, Micaela M. Hernberg, Pia P. Vihinen, Veli-Matti Kähäri, Ilkka O. Koskivuo

    Changes in the incidence of melanoma in children and adolescents have been reported in Europe and in the USA in the recent decades.The aim of this study was to examine the incidence of paediatric a...


  • Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis

    by Paulina Moreno-Layseca, Niklas Z. Jäntti, Rashmi Godbole, Christian Sommer, Guillaume Jacquemet, Hussein Al-Akhrass, James R. W. Conway, Pauliina Kronqvist, Roosa E. Kallionpää, Leticia Oliveira-Ferrer, et al.

    Spatially controlled, cargo-specific endocytosis is essential for development, tissue homeostasis and cancer invasion. Unlike cargo-specific clathrin-mediated endocytosis, the clathrin- and dynamin-independent endocytic pathway (CLIC-GEEC, CG pathway) is considered a bulk internalization route for the fluid phase, glycosylated membrane proteins and lipids. While the core molecular players of CG-endocytosis have been recently defined, evidence of cargo-specific adaptors or selective uptake of proteins for the pathway are lacking. Here we identify the actin-binding protein Swiprosin-1 (Swip1, EFHD2) as a cargo-specific adaptor for CG-endocytosis. Swip1 couples active Rab21-associated integrins with key components of the CG-endocytic machinery—Arf1, IRSp53 and actin—and is critical for integrin endocytosis. Through this function, Swip1 supports integrin-dependent cancer-cell migration and invasion, and is a negative prognostic marker in breast cancer. Our results demonstrate a previously unknown cargo selectivity for the CG pathway and a role for specific adaptors in recruitment into this endocytic route.


  • Open Access

    Alpha band frontal connectivity is a state-specific electroencephalographic correlate of unresponsiveness during exposure to dexmedetomidine and propofol

    by Roosa E. Kallionpää, Katja Valli, Annalotta Scheinin, Jaakko Långsjö, Anu Maksimow, Tero Vahlberg, Antti Revonsuo, Harry Scheinin, George A. Mashour, Duan Li